tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2023 Dec 15;19(3):2278376.
doi: 10.1080/21645515.2023.2278376. Epub 2023 Nov 16. Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects
Hideaki Kato[SUP] 1 [/SUP], Takayuki Kurosawa[SUP] 2 [/SUP], Kazuo Horikawa[SUP] 3 [/SUP], Yayoi Kimura[SUP] 3 [/SUP], Kei Miyakawa[SUP] 4 [/SUP], Akihide Ryo[SUP] 5 [/SUP], Atsushi Goto[SUP] 6 [/SUP]
Affiliations
Antibody obtained by the coronavirus disease-19 (COVID-19) mRNA vaccine declines over time, and additional vaccinations are offered. It is not clear how repeated vaccination affects humoral immunity in uninfected individuals. We analyzed immunoglobulin G for spike protein (S-IgG) titers in COVID-19 uninfected and infected individuals vaccinated up to six times. The geometric mean S-IgG titers were 575.9 AU/mL and 369.0 AU/mL in those who received 6 and 5 doses less than 180 days after the last vaccination in uninfected subjects. In the 180-360 days after the last vaccination, the geometric mean S-IgG titers were 237.9 AU/mL and 128.6 AU/mL in the uninfected subjects who underwent five-dose and four-dose groups, respectively. Multivariate analysis showed that S-IgG titer increased 1.261-fold with each additional dose of mRNA vaccine. The S-IgG titers were 2.039-fold higher in the COVID-infected subjects compared to uninfected subjects. The positivity rate of nucleocapsid antibodies, suggesting a history of COVID-19, decreased 82% and 30% of COVID-infected cases after 180 and 360 days of infection, respectively. This result suggested that repeated vaccination with the COVID-19 mRNA vaccine may increase antibody titer in uninfected subjects.
Keywords: Antibody; COVID-19; COVID-naïve; Lumipulse; SARS-CoV-2; additional vaccination; chemiluminescent enzyme immunoassay; humoral immunity; nucleocapsid protein; spike protein.
. 2023 Dec 15;19(3):2278376.
doi: 10.1080/21645515.2023.2278376. Epub 2023 Nov 16. Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects
Hideaki Kato[SUP] 1 [/SUP], Takayuki Kurosawa[SUP] 2 [/SUP], Kazuo Horikawa[SUP] 3 [/SUP], Yayoi Kimura[SUP] 3 [/SUP], Kei Miyakawa[SUP] 4 [/SUP], Akihide Ryo[SUP] 5 [/SUP], Atsushi Goto[SUP] 6 [/SUP]
Affiliations
- PMID: 37969091
- DOI: 10.1080/21645515.2023.2278376
Antibody obtained by the coronavirus disease-19 (COVID-19) mRNA vaccine declines over time, and additional vaccinations are offered. It is not clear how repeated vaccination affects humoral immunity in uninfected individuals. We analyzed immunoglobulin G for spike protein (S-IgG) titers in COVID-19 uninfected and infected individuals vaccinated up to six times. The geometric mean S-IgG titers were 575.9 AU/mL and 369.0 AU/mL in those who received 6 and 5 doses less than 180 days after the last vaccination in uninfected subjects. In the 180-360 days after the last vaccination, the geometric mean S-IgG titers were 237.9 AU/mL and 128.6 AU/mL in the uninfected subjects who underwent five-dose and four-dose groups, respectively. Multivariate analysis showed that S-IgG titer increased 1.261-fold with each additional dose of mRNA vaccine. The S-IgG titers were 2.039-fold higher in the COVID-infected subjects compared to uninfected subjects. The positivity rate of nucleocapsid antibodies, suggesting a history of COVID-19, decreased 82% and 30% of COVID-infected cases after 180 and 360 days of infection, respectively. This result suggested that repeated vaccination with the COVID-19 mRNA vaccine may increase antibody titer in uninfected subjects.
Keywords: Antibody; COVID-19; COVID-naïve; Lumipulse; SARS-CoV-2; additional vaccination; chemiluminescent enzyme immunoassay; humoral immunity; nucleocapsid protein; spike protein.